An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Part of paid clinical trials in Grand Rapids, Michigan.

Sponsor
Repertoire Immune Medicines
Study ID
NCT07293754
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Malignant Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RPTR-1-201 — DRUG
    RPTR-1-201
  • PD-1 / PD-L1 monoclonal antibody — DRUG
    PD-1/PD-L1 monoclonal antibody

Study Details

This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.

Key Dates

First listed
Dec 19, 2025
Start date
Dec 12, 2025
Status verified
Feb 2026
Primary completion
Dec 15, 2028
Completion
Apr 15, 2029

Study Design

Enrollment
150 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Monotherapy
    Participants receive RPTR-1-201 at doses and schedules defined by the trial protocol.
  • Experimental: Combination
    Participants receive RPTR-1-201 in combination with an approved or investigational PD-1 monoclonal antibody at doses and schedules defined by the trial protocol.

Primary Outcome Measure

Number of participants with dose-limiting toxicities and treatment-emergent adverse events. [ Time Frame: From first dose through 30 days after last dose of trial treatment. ]

Locations (1)

FacilityCityStateZIPSite coordinators
START MidwestGrand RapidsMichigan49546
Jacob Goldberg
[email protected]
616-954-5561

Find similar trials in Grand Rapids, MI

By research site
START Midwest· Grand Rapids, MI

Related Studies